DXB Stock Discussion
Dimerix Ltd Description
Dimerix Bioscience Ltd, formerly Dimerix Bioscience Pty Ltd, is engaged in developing and commercializing drug therapies and drug discovery tools. The Company’s business activity focuses on the clinical development of the Company’s therapeutic product (DMX200), which is targeted at treatind patients with chronic kidney disease; the development of other therapeutic oppurtunities generated from the use of its cell-based drug discovery assay technology (know as Receptor-HIT), and growing its assay business through the use of Receptor-HIT to assist third parties in their own drug discovery and development processes through contract research. DMX200 is a therapeutic approach to treating chronic kidney disease. It comprises two drugs: irbesartan and propagermanium.
Industry: Biotechnology
Keywords: Health Disease Drugs Life Sciences Health Sciences Drug Discovery Therapeutic Product
Recent Comments
- TRTCryptoCraig on Bad Quotes for 28 May...
- TraderMike on Bad Quotes for 28 May...
- TraderMike on Market Recap for Friday, May 31, 2024
- PleasantTurtle699 on Market Recap for Friday, May 31, 2024
- TraderMike on Market Recap for Friday, May 31, 2024
From the Blog
Featured Articles